What is ATNM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ATNM?

P/E (TTM) is 3.00 and 52-week range is $0.74 to $1.74 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ATNM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ATNM?

The company profile lists revenue (TTM) near $35M, net income (TTM) near $23M, EPS (TTM) near $0.36 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Actinium Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 31.4M shares outstanding, ISIN US00507W2061 when available from company profile and filing metadata.

Actinium Pharmaceuticals Inc

$ATNM

Health Care · Biotechnology

IR Run Scenarios

$1.10

+1.85%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 25 full-time employees. The company went IPO on 2014-03-26. The firm is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The firm is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.

Employees

Website

www.actiniumpharma.com/

IPO

2014-03-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)